Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Post a job

Workshop

[Free Online workshop] Immunogenicity of Biologic Drugs – Clinical Relevance case studies, Predictive Tools & Challenges with New modalities


Speakers: Steve Swanson, Genentech; Yi Wen , Eli Lilly; Francesca Civoli , Coherus BioSciences; Vibha Jawa , BMS; Wenyu Liu , Genentech; Lin-zhi Chen ,Boehringer Ingelheim Pharmaceuticals, Inc.; Mauricio Maia, Genentech; Sofie Pattyn, ImmunXperts; Cathie (Dong) Xiang, Amgen; Ronit Mazor, FDA; João Pedras-Vasconcelos, FDA; Morten Nielsen, EIR Sciences, DTU
Organizers: Ola Saad, Sivan Cohen and Surinder Kaur (Genentech, Inc.)
Date: 2022-09-15- 09/16/2022
Time: 8:30-12:30 Pacific Time
Registration fee: Free
Location: Online via zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2022-09-14  (it will close sooner if the seating cap is reached)

About the Topic

The Immunogenicity of Biologic Drugs workshop is a 2 half-day program aimed to promote the discussion and exchange of scientific ideas from the FDA and leading industry and academic experts on the application and clinical relevance of immunogenicity mitigation and assessment assays. Tentative topics covered in this workshop include, but are not limited to:

  • ADA assay Development, Validation, and interpretation (drug and target interference, pre-existing antibodies)

  • Advancements of predictive immunogenicity risk tools (in vitro, in silico) and lessons learned with implementation

  • Bioanalytical Strategies for New Modalities 

  • Highlights from and comments around 2022 FDA Immunogenicity Labeling Draft Guidance

Note: This is an online meeting, The Zoom link will be sent to the registrants 1+ days before the event.


About the Speakers

  • Steve Swanson (Senior Principal Scientist, Genentech)
  • Yi Wen (Advisor, Eli Lilly)
  • Francesca Civoli (Vice President Bioanalytical Sciences, Coherus BioSciences)
  • Vibha Jawa (Executive Director, BMS)
  • Wenyu Liu (Senior Scientist, Genentech)
  • Lin-zhi Chen (Sr. Research Fellow/ Bioanalytical Group Leader, Boehringer Ingelheim Pharmaceuticals, Inc.)
  • Mauricio Maia (Senior Principal Scientist, Genentech)
  • Sofie Pattyn (Chief Technology Officer, ImmunXperts a Q2 Solutions Company)
  • Cathie (Dong) Xiang (Amgen)
  • Morten Nielsen (CEO EIR Sciences; Professor at DTU - Technical University of Denmark)
  • Ronit Mazor (Principal Investigator, CBER, FDA)
  • João Pedras-Vasconcelos (Product Quality and Immunogenicity Senior Staff Fellow, CDER, FDA)

Agenda:

Sep. 15th 

Time (PDT)

Time (EST)

Topic

Presenter

8:30-8:45 am 

11:30-11:45am 

Welcome & Workshop Introduction

Ola Saad & Sivan Cohen

8:45-9:15 am 

11:45-11:15am 

Immunogenicity Risk Assessments to Drive the Bioanalytical Strategy for Novel Modalities

Vibha Jawa, Executive Director, BMS

9:15-9:45 am 

12:15-12:45pm 

Immunogenicity of AAV Vectors in Gene Therapy

Ronit Mazor, Principal Investigator, CBER, FDA

9:45-10:15 am 

12:45-1:15 pm 

Recent Updates to HLA-II Prediction Algorithms, and Their Application to Assess the Immunogenicity Risk of Biotherapeutics

Morten Nielsen, CEO EIR Sciences; Professor at DTU

10:15-10:30am

1:15-1:30pm

Break

 -

10:30-11:00am

1:30-2:00pm

Early In Vitro Immunogenicity Assessment Tools

Sofie Pattyn, Chief Technology Officer, ImmunXperts a Q2Solutions Company

11:00-11:30am

2:00-2:30pm

DC Internalization and Innate Activation for Immunogenicity Risk Assessment of Antibodies

Yi Wen, Advisor, Eli Lilly

11:30-12:00pm

2:30-3:00pm

Use of In Vitro Cell Based Assays to Assess Potential Immunogenicity Risk of Critical Quality Attributes 

Cathie (Dong) Xiang, Scientist, Amgen

12:00-12:30pm

3:00-3:30pm

PANEL DISCUSSION

All speakers

 

Sep. 16th 

Time (PDT)

Time (EST)

Topic

Presenter

8:30 -8:45 am 

11:30-11:45am 

Day 2 Welcome & Introduction

Ola Saad & Sivan Cohen

8:45 -9:15 am 

11:45-11:15am 

Immunogenicity of Biologic Therapeutics & Clinical Relevance

Steve Swanson, Senior Principal Scientist, Genentech

9:15 -9:45 am 

12:15-12:45pm 

Immunogenicity Information in Labeling- Highlights from the New FDA Draft Guidance

João Pedras-Vasconcelos, Product Quality and Immunogenicity Senior Staff Fellow, CDER, FDA

9:45-10:15 am 

12:45-1:15 pm 

LC/MS for ADA Analysis: Simultaneous Quantitation and Isotyping and Beyond

Lin-zhi Chen, Sr. Research Fellow/ Bioanalytical Group Leader; Boehringer Ingelheim Pharmaceuticals, Inc.

10:15-10:30am

1:15-1:30pm

Break

 

10:30-11:00am

1:30-2:00pm

Investigating the Clinical Relevance of the Immunogenicity for a Bispecific Antibody 

Wenyu Liu, Senior Scientist, Genentech

11:00-11:30am

2:00-2:30pm

Challenges in the Assessment of Biosimilar Immunogenicity Data 

Francesca Civoli, Vice President Bioanalytical Sciences, CoherusBioSciences

11:30-12:00pm

2:30-3:00pm

Immunogenicity Profile of the Port Delivery System with Ranibizumab

Mauricio Maia Senior Principal Scientist, Genentech

12:00-12:30pm

3:00-3:30pm

PANEL DISCUSSION

All Speakers


2024-06-20, Alzheimer's Disease: Untangling What We Thought We Knew and Future Precision Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-08-14, [Free Online] Advances in Cancer Therapeutics
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projections for Antibodies and Novel Therapeutic Modalities: Antibodies, ADCs, Covalent Inhibitors, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
©Pharmaceutical & BioScience Society, International; Last Modified: 6/15/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Simulations Plus Join us for MIDD+ San Francisco, a free event June 6-7. Hear scientific presentations from industry leaders, train with experts & connect with peers.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Submit a Text Ad